Log on / register
BioMed Central home | Journals A-Z | Feedback | Support | My details

Email this article to a friend

Conclusions regarding the efficacy of treatments for neuroleptic malignant syndrome should be tempered given poor quality data, regardless of the analysis conducted

Darren M Roberts email and Jason A Roberts

Critical Care 2007, 11:413doi:10.1186/cc5786



See related research by Ruelbach et al. http://ccforum.com/content/11/1/R4 and related letter by Brvar and Bunc, http://ccforum.com/content/11/3/415

Your name*
Your email address*
Recipient's email address*
(multiple email addresses should be separated with commas)
Email format
Please type your message into the box below:
Terms and Conditions Privacy statement Information for advertisers Jobs at BMC Contact us
© 1999-2009 BioMed Central Ltd unless otherwise stated. Part of Springer Science+Business Media.